Company Overview

GSK plc, formerly known as GlaxoSmithKline plc, is a leading global biopharmaceutical company with a rich heritage dating back to its founding in 1715. Headquartered in London, United Kingdom, GSK is dedicated to bringing together science, technology, and talent to drive the fight against disease. The company focuses on the discovery, development, and manufacturing of innovative medicines, vaccines, and specialty treatments. GSK operates commercially and through extensive research & development segments, aiming to improve human health worldwide.

Business Segments and Operations

GSK's operations are primarily structured around its key therapeutic areas, focusing on scientific innovation and patient needs.

Specialty Medicines

This is GSK's largest business segment, which has demonstrated consistent double-digit sales growth, particularly in Respiratory, Immunology & Inflammation, Oncology, and HIV during Q2 2025. The company develops cutting-edge treatments for a range of complex diseases and conditions.

Vaccines Portfolio

GSK is a global leader in vaccines, providing more than 20 different vaccines that protect individuals from a wide array of diseases and infections. Key vaccines include those for Shingles, Meningitis, RSV, Seasonal Influenza, Hepatitis, Diphtheria, Tetanus, Acellular Pertussis, Rotavirus, Pertussis, Polio, Haemophilus Influenzae type b (Hib), Invasive Diseases, Pneumonia, Acute Otitis Media, Measles, Mumps, Rubella, Chickenpox, and Human Papillomavirus (HPV).

General Medicines

The company continues to offer a portfolio of essential medicines that treat common conditions. This includes treatments for asthma, chronic obstructive pulmonary disease (COPD), bacterial infections, benign prostatic hyperplasia, allergic rhinitis, and inflammatory skin conditions. The focus remains on inhaled medicines, antibiotics, and dermatological treatments.

Financial Performance

GSK has showcased strong financial performance driven by its specialty medicines and vaccine portfolios, alongside disciplined cost management.

2024 Annual Results

For the full year 2024, GSK plc reported annual revenue of approximately $40.095 billion, representing a 6.28% increase from 2023. The company achieved excellent performance, with significant sales and core operating profit growth, largely propelled by the accelerating momentum of its specialty medicines portfolio.

2025 Performance Outlook

GSK's strong growth trajectory continues into 2025, with another quarter of excellent performance primarily driven by Specialty Medicines. The company has revised its outlook upwards and now expects:

- Turnover growth of 3% to 5%

- Core operating profit growth of 6% to 8%

- Core EPS growth of 6% to 8%

Key Financial Highlights:

- Dividends: Q4 2024 dividend of 16p declared; 61p for FY 2024; 64p expected for 2025.

- Share Buyback: £822 million spent in H1 2025 as part of the £2 billion share buyback programme announced at FY 2024.

- Q1 2025 Performance: Sales increased by 4% and core operating profit grew by 5%.

Research & Development Pipeline

GSK maintains a robust and innovative R&D pipeline, investing significantly in future breakthroughs. The company's R&D efforts are concentrated on developing 14 key medicines and vaccines expected to launch between 2025 and 2031, each with the potential for over £2 billion in annual sales. GSK has reported substantial progress, including 3 major FDA approvals in the current year, 16 assets now in late-stage development, and 4 more promising therapies for cancer, liver disease, and HIV expected to enter Phase III or pivotal development by the end of the year.

Recent Pipeline Progress

GSK anticipates 5 major new product approvals in 2025, including treatments like Blenrep for multiple myeloma and depemokimab for severe asthma and CRSwNP. Additionally, the company has planned Phase III readouts for camlipixant (refractory chronic cough) and tebipenem (complicated UTI).

Strategic Partnerships and Collaborations

To further strengthen its pipeline and capabilities, GSK actively pursues strategic partnerships and collaborations. Notably, the company has a collaboration agreement with CureVac aimed at developing mRNA vaccines for infectious diseases. These strategic alliances are crucial for accelerating innovation and expanding GSK's therapeutic reach.

Long-term Growth Outlook

GSK has further enhanced its long-term growth projections, now expecting sales to exceed £40 billion by 2031 (up from the previous forecast of >£38 billion). The company is strategically increasing and prioritizing R&D investments in promising new long-acting and specialty medicines across its core areas: Respiratory, Immunology & Inflammation, Oncology, and HIV.

Corporate Evolution

The company was formerly known as GlaxoSmithKline plc and officially changed its name to GSK plc in May 2022. This rebranding signifies its transformation and sharpened focus on its core biopharmaceutical operations.

GSK's strategic emphasis on specialty medicines, vaccines, and cutting-edge R&D positions it as a pivotal player in addressing global health challenges. The company's consistent financial performance, robust pipeline, and unwavering commitment to innovation continue to solidify its leadership position in the global pharmaceutical industry, promising sustainable growth for its shareholders.